Observed Signal · Sep 24, 2026 · Funding · Source: First Analysis

First Analysis acted as the exclusive financial advisor to Phigenics in its majority growth investment from Battery Ventures

Executive Signal Summary

First Analysis acted as the exclusive financial advisor to Phigenics, a healthcare-focused water risk management platform, in its majority growth investment from Battery Ventures. The partnership aims to support Phigenics' growth through increased investment in existing and new products, as well as expansion into new markets. Phigenics serves more than 250 customer organizations, including major hospital systems and VA facilities, and operates accredited laboratories in Illinois and Arkansas.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This transaction highlights the growing strategic importance of water risk management in healthcare and adjacent sectors, and reflects an investment trend toward specialized compliance and safety platforms. First Analysis' advisory role underscores the value of specialized investment banking expertise in this niche.

SIGNAL RADAR

Track First Analysis Signals & Market Shifts in Real-Time

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • On September 24, 2026, First Analysis announced it acted as exclusive financial advisor to Phigenics in a majority growth investment from Battery Ventures.
  • Phigenics is a healthcare-focused water risk management platform serving more than 250 customer organizations, including major hospital systems and VA facilities.
  • Phigenics is headquartered in Warrenville, Illinois, with accredited laboratories in Warrenville and Fayetteville, Arkansas.
  • Phigenics CEO Mark Crockett stated that partnering with Battery will provide additional resources and expertise to accelerate innovation and expand capabilities.
  • Battery Ventures, founded in 1983, invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv.

Connected Companies & Entities

“First Analysis, an investment bank, acted as the exclusive financial advisor to Phigenics in the majority growth investment from Battery Ven...”

“Battery Ventures is the investor acquiring a majority growth stake in Phigenics, a global investment firm founded in 1983 with offices in mu...”

Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: First Analysis•Published: Sep 24, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

FundingSep 2, 2026

UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform

London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.

Read assessment
FundingNov 10, 2026

Proximal Ventures Raises $27.5M for AI Drug Development Fund

Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.

Read assessment
FinancialsNov 11, 2026

Switchpoint Bio Raises $5.3M for Drug Response Insights

Switchpoint Bio, a Helsinki-Cambridge biotech startup, emerged from stealth with $5.3 million in pre-seed funding, including a $5 million investment from Treehouse Delmar Investments. The company combines precision epigenomic profiling and AI to measure disease and treatment-induced biological changes from blood samples, aiming to provide drug developers with insights into patient responses. The platform targets DNA methylation in epigenomically active regions, offering scalable, cost-efficient coverage for drug development. Founded by Samuel Myllykangas and Jason Buenrostro, the team is validating its approach in autoimmune diseases like lupus while engaging pharma partners. The funding will support clinical validation, platform development, and team expansion.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for First Analysis & competitors in your briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime